Abstract:High-dose radiation exposure results in gastrointestinal (GI) acute radiation syndrome identified by the destruction of mucosal layer, intestinal epithelial barrier dysfunction, and aberrant inflammatory responses. In addition, radiation causes gut microbiome dysbiosis characterized by diminished microbial diversity, reduction in the abundance of beneficial commensal bacteria, and the spread of bacterial pathogens that trigger the recruitment of immune cells and the production of pro-inflammatory factors that lead to further GI tissue damage. Currently, there are no FDA-approved countermeasures that can treat radiation-induced GI injury. To meet this critical need, Synedgen Inc., has developed a glycopolymer radiomitigator (MIIST305) that is specifically targeted to the GI tract which acts by intercalating into the mucus layer and the glycocalyx of intestinal epithelial cells that could potentially ameliorate the deleterious effects of radiation. Male C57BL/6J adult mice were exposed to 13 Gy total body X-irradiation with 5% bone marrow shielding and MIIST305 was administered on days 1, 3, and 5 post-irradiation. Approximately 85% of the animals survived the irradiation exposure and were apparently healthy until the end of the 30-day study period. In contrast, no control, vehicle-treated animals survived past day 10 at this radiation dose. We show that MIIST305 improved intestinal epithelial barrier function and suppressed systemic inflammatory response mediated by radiation-induced pro-inflammatory cytokines. Taxonomic profiling and community structure of the fecal and colonic mucosa microbiota demonstrated that MIIST305 treatment increased microbial diversity and restored abundance of beneficial commensal bacteria, including Lactobacillus and Bifidobacterium genera, while suppressing potentially pathogenic bacteria compared with vehicle-treated animals. In summary, MIIST305 is a novel GI-targeted therapeutic that greatly enhances survival in mice exposed to lethal radiation and protects the GI tract from injury by restoring a balanced gut microbiota and effectively reducing proinflammatory responses. Further development of this drug as an FDA-approved medical countermeasure will be of critical importance in the event of a radiation public health emergency.

Intestinal Delivery of ROS-scavenging Carbonized Polymer Dots for Full-Course Treatment of Acute and Chronic Radiation Enteritis

Dopamine-derived Nanoparticles for the Protection of Irradiation-Induced Intestinal Injury by Maintaining Intestinal Homeostasis.

Oral Curcumin–Thioketal–Inulin Conjugate Micelles against Radiation–Induced Enteritis

Colon‐targeted Release of Gel Microspheres Loaded with Antioxidative Fullerenol for Relieving Radiation‐Induced Colon Injury And Regulating Intestinal Flora

Smart Oral Administration of Polydopamine‐Coated Nanodrugs for Efficient Attenuation of Radiation‐Induced Gastrointestinal Syndrome

Exosome-coated Polydatin Nanoparticles in the Treatment of Radiation-Induced Intestinal Damage.

Broad-Spectrum Reactive Oxygen Species Scavenging And Activated Macrophage-Targeting Microparticles Ameliorate Inflammatory Bowel Disease

Graphdiyne nanoradioprotector with efficient free radical scavenging ability for mitigating radiation-induced gastrointestinal tract damage

Regulation of gut microbiome with redox responsible bacterial cellulose hydrogel for precision chemo-radiotherapy of intestinal cancer

Oral administration of probiotic spore ghosts for efficient attenuation of radiation-induced intestinal injury

A ferroptosis-targeting ceria anchored halloysite as orally drug delivery system for radiation colitis therapy

Colon-targeted Oral Nanoparticles Based on ROS-scavenging Hydroxyethyl Starch-Curcumin Conjugates for Efficient Inflammatory Bowel Disease Therapy.

Phycocyanin Ameliorates Radiation-Induced Acute Intestinal Toxicity by Regulating the Effect of the Gut Microbiota on the TLR4/Myd88/NF-κB Pathway

Gram-scale preparation of quercetin supramolecular nanoribbons for intestinal inflammatory diseases by oral administration

Oral Codelivery of WR-1065 Using Curcumin-Linked ROS-Sensitive Nanoparticles for Synergistic Radioprotection

Efficient Active Hydrogen Delivery for Drug-Free Radiation Enteritis Therapy

Polycatechol-Derived Mesoporous Polydopamine Nanoparticles for Combined ROS Scavenging and Gene Interference Therapy in Inflammatory Bowel Disease

Intestinal microecological transplantation for a patient with chronic radiation enteritis: A case report

MIIST305 mitigates gastrointestinal acute radiation syndrome injury and ameliorates radiation-induced gut microbiome dysbiosis

ROS-responsive Nanoparticles Targeting Inflamed Colon for Synergistic Therapy of Inflammatory Bowel Disease Via Barrier Repair and Anti-Inflammation

Enhancing radioprotection: A chitosan-based chelating polymer is a versatile radioprotective agent for prophylactic and therapeutic interventions against radionuclide contamination